Novartis International AG’s Collaboration And Exclusive Option Agreement With IFM Due

Hogan Lovells team advised Novartis in a collaboration and option agreement with IFM Due, a subsidiary of Boston-based biopharmaceutical company IFM Therapeutics.

Under the terms of the agreement, Novartis will make fixed payments sufficient to fully finance IFM Due’s research and development costs for the cGAS/STING program in exchange for the option to acquire the IFM Due subsidiary. Upon option exercise, IFM Due’s shareholders will be entitled to consideration in aggregate value of up to $840 million, including an upfront payment upon option closing and other contingent consideration.

IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.

The Hogan Lovells team was led by New York Corporate partners Adam Golden (Picture) and Michael Szlamkowicz, supported by Corporate senior associates Jeffrey Jay and Allison Netto, and associate Katie Haines; Employment partner Michael DeLarco and senior associate David Mitchell; Tax partner Christine Lane and associate Catherine Chen; Benefits partner Martha Steinman and senior associate Ben Clark; and Antitrust partner Leigh Oliver, and senior associate Lauren Battaglia.

Involved fees earner: Lauren Battaglia – Hogan Lovells; Catherine Chen – Hogan Lovells; Ben Clark – Hogan Lovells; Michael DeLarco – Hogan Lovells; Adam Golden – Hogan Lovells; Katie Haines – Hogan Lovells; Jeffrey Jay – Hogan Lovells; Christine Lane – Hogan Lovells; David Mitchell – Hogan Lovells; Allison Netto – Hogan Lovells; Leigh Oliver – Hogan Lovells; Martha Steinman – Hogan Lovells; Michael Szlamkowicz – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Novartis AG;

Author: Ambrogio Visconti